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ABSTRACT
Cystic fibrosis is a common genetic condition
and abnormal glucose handling leading to
cystic fibrosis-related diabetes (CFRD) is a
frequent comorbidity. CFRD is mainly thought
to be the result of progressive pancreatic
damage resulting in beta cell dysfunction and
loss of insulin secretion. Whilst Oral Glucose
Tolerance Testing is still recommended for
diagnosing CFRD, the relationship between
glucose abnormalities and adverse outcomes in
CF is complex and occurs at stages of
dysglycaemia occurring prior to diagnosis of
diabetes by World Health Organisation criteria.
Insulin remains the mainstay of treatment of
CF-related glucose abnormalities but the timing
of insulin commencement, optimum insulin
regime and targets of glycaemic control are not
clear. These complexities are compounded by
common issues with nutritional status, need for
enteral feeding, steroid use and high disease
burden on CF patients.




Cystic fibrosis (CF) is a common life-limiting
autosomal recessive condition with the highest
prevalence in populations with Northern
European ancestry. The disease is caused by
gene mutation causing defective function of a
chloride channel—the cystic fibrosis
transmembrane conductance regulator
(CFTR)—which is vital for mucociliary
clearance in the airways [1]. Cystic fibrosis
impacts several organ systems including the
liver, skin sweat glands and pancreas, but its
classical impact on morbidity and mortality is
via bronchiectasis, airways obstruction and
progression to respiratory failure.
Abnormalities of glucose metabolism are an
important co-morbidity of CF. Classically,
progressive loss of beta cell function in CF
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leads to abnormal glucose levels and
progression to cystic fibrosis-related diabetes
(CFRD) [2–4]. The development of glucose
abnormalities is recognised to herald a clear
increase in morbidity and mortality in patients
with CF, leading to a focus on identifying and
controlling disordered glucose metabolism in
CF [5, 6].
The management of CFRD is complex and
importantly it differs significantly from that of
type 1 and type 2 diabetes. Management of
CFRD requires a multidisciplinary approach to
attempt to ensure the best possible clinical
outcome, whilst minimising
treatment-associated adverse events.
This article explores the pathophysiology,
diagnosis and clinical impact of glucose
abnormalities in CF and discusses the
approach to treatment of this challenging
problem.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
PATHOPHYSIOLOGY
CFRD is primarily characterisable as a defect of
insulin release resulting from the secretions
blocking pancreatic ducts, autodigestion,
oxidative stress and destructive fibrotic
pancreatic disease that ultimately destroys islet
cell function [2–4]. Pancreatic beta cell function
and first phase insulin secretion have been
shown to be reduced in CFRD when compared
to normal glucose tolerance (NGT) patients
with CF where no difference is observed in
insulin resistance [7]. Patients with CF also have
more rapid small bowel glucose absorption
further exacerbating postprandial glucose
excursions [8].
Patients with CF have also been shown to
have decreased GLP-1 activity compared to
normal controls, which may contribute to
glucose abnormalities [9]. CF is a complex
multisystem disease, and multiple defects in
nutritional status and metabolism also
contribute to observed glucose abnormalities.
Table 1 summarises these defects and their
consequences for glucose metabolism.
EPIDEMIOLOGY
CFRD is clinically and pathophysiologically
distinct from either type 1 or type 2 diabetes.
It occurs in children and young adults with a
median age at onset of 20 years. It appears to
develop earlier in female than male patients
[10]. Of 158 adults (categorised by WHO OGTT
criteria or physician insulin initiation) over
16 years of age attending a CF service in the
UK, 51 (32.3%) had CFRD, 24 (15.2%) had
impaired fasting glucose or impaired glucose
tolerance, and 83 (52.5% ) had normal glucose
tolerance [11]. CFRD appears to be more
common in patients who are homozygous for
the most common CFTR gene mutation,
DF508.10 [3]. Ketoacidosis is rare but can occur
if CFRD goes untreated or in the presence of
significant intercurrent infection [12]. As the
age at which CFRD and type 1 diabetes usually
present overlaps, it is important to remember
that patients with CF can also develop type 1
diabetes.
The recent history of CF has been one of
greatly improved survival. Improvements in
physiotherapy and drugs to clear mucus from
the lungs and aggressive treatment of infection,
combined with pancreatic exocrine
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supplements and enhanced nutrition, have all
contributed to significant improvements in
morbidity and mortality in patients with cystic
fibrosis. In Europe a significant reduction in
potential years life lost (PYLL) for patients
between 0 and 30 years old has been
described. In males, the standardised PYLL
decreased from 14.65 (11.37–17.93) lost years
per million persons per year in 1994 to 7.49
(6.14–8.84) in 2010 [13]. In Canada, median
survival age increased from 31.9 years (95% CI
28.3–35.2 years) in 1990 to 49.7 years (95% CI
46.1–52.2 years) in the 5-year window ending in
2012 [14]. As patients with CF live longer it is
likely therefore that the prevalence of CFRD will
increase.
DIAGNOSIS
The onset of CFRD cannot reliably be detected
symptomatically, with around 2/3 of patients
asymptomatic at diagnosis [15]. Given the
potential impact of CFRD on morbidity and
mortality, a reliable biochemical screening test
for CFRD is vital. There is general agreement
between national and international societies
that CFRD should be diagnosed using the
standard 75 g Oral Glucose Tolerance Test
(OGTT) with the general recommendation that
this should be carried out annually in all
patients from childhood [16, 17]. Use of the
OGTT in the diagnosis of CFRD does however
have a number of disadvantages. First, it is a
time-consuming investigation for patients and
staff to perform. Furthermore, the OGGT was
primarily developed as a way of predicting risk
of microvascular and macrovascular
complications of hyperglycaemia, and as such
it does not necessarily predict the risks and
complications associated with dysglycaemia in
CF. The response of measured glucose to an oral
glucose challenge is especially variable in
Table 1 Factors impacting on glucose regulation in CF
System Defect Impact on metabolism




Exocrine pancreas Reduced pancreatic enzyme production Malabsorption of fat, protein and carbohydrate
Gut Malabsorption of fat and protein
Rapid glucose absorption
Less active GLP-1
Rapid postprandial glucose excursions
Low glucose preprandial
Reduced insulin and increased glucagon secretion




Reduced response to hypoglycaemia




Adrenal Cortisol response to intercurrent infections
Use of exogenous steroid treatment
Stress hyperglycaemia
Steroid related hyperglycaemia
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patients with CF. In one study glucose tolerance
improved [from normal to impaired glucose
tolerance (IGT) or from CFRD to normal or IGT]
in 18% of patients over 4 years whilst 19%
worsened in category over the same time period
[18]. Crucially, early CFRD is classically
characterised by postprandial glucose
excursions secondary to loss of first phase
insulin. In order to have an optimal chance of
detecting this abnormality a 1 h glucose
estimation would be required during OGTT,
and indeed it has been shown that 1 h glucose
levels are a better predictor of decline in
pulmonary function than 2 h levels during
GTT [19].
Whilst HbA1c is now accepted as a
diagnostic tool within the field of diabetes, it
is difficult to interpret as a diagnostic test for
CFRD. Relatively brief periods of postprandial
hypoglycaemia with low normal pre-meal
glucose levels have the potential to lead to
reassuringly normal HbA1c values. Studies
assessing the consistency of HbA1c as a
measure of mean blood glucose in CFRD and
HbA1c have shown conflicting results [20, 21].
CFRD is additionally associated with a lower
than normal red cell lifespan, which could
reduce diagnostic utility [22]. In one
prospective study an HbA1c of[46 mmol/mol
showed a positive predictive value of 50% when
compared with OGGT [15]. In another study
elevated HbA1c[42 mmol/mol was seen in
only 38% of patients with diabetes, confirming
a poor sensitivity as a diagnostic test in CFRD
[7]. If HbA1c is to have utility, lower levels will
need to be considered as clinically important.
An HbA1c C40 mmol/mol has been proposed as
a diagnostic level for CFRD screening and is
suggested to reduce the need for an OGTT by
50.7% [23]. A systematic review of screening
tests for CFRD agreed that the sensitivity of
HbA1c is too low to recommended it as a
diagnostic test [24].
Given that pulmonary consequences of
CFRD are known to occur when only 1 h
postprandial glucose is elevated when
measured during an OGTT, there is theoretical
merit in using 1 h levels measured by capillary
blood glucose (CBG) monitoring or continuous
glucose monitoring when performing this
investigation [25–28].
Our local practice is to recommend annual
OGTT for all patients from age 10 years and 1 h
postprandial CBG monitoring in patients where
clinically indicated by declining lung function,
recurrent infection or weight loss. Table 2 shows
a summary of diagnostic guidelines.
IMPACT ON PROGNOSIS
Abnormalities of glucose metabolism have a
clear association with morbidity and mortality
in CF patients. It is less clear whether
hyperglycaemia or insulin deficiency have a
causal relationship with poor outcomes or are
simply markers of more advanced or
complicated disease.
Worsening lung function is clearly
associated with glucose abnormalities, and a
decline in pulmonary function appears to be
related to the severity of glucose intolerance
and insulin deficiency [18]. Patients with CFRD
have more episodes of infection and have
higher rates of colonisation with important
pathogenic organisms such as
BurkholderiaCepacia and Aspergillus
suggesting impaired immunity [29]. It has
been suggested that an association between
poor lung function and dysglycaemia may be
more important in females [30].
In a UK registry study of 5892 patients with
CF the presence of diabetes was an independent
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risk factor for death (hazard ratio 1.31 (95% CI
1.03–1.67)] [31]. Registry data from the US show
that in patients with CF, controlling for other
risk factors, diabetes is associated with a 55%
increase in 5-year mortality [32].
These consistent associations between
insulinopenicdysglycaemia and adverse
outcome suggest correcting glucose
abnormalities with insulin or insulin
secretagogues may confer benefit.
Whilst the the primary focus in CFRD is on
lung function and nutritional status, it is
important to remember that, as with all types
of diabetes mellitus, effective screening for
microvascular complications is required.
Compared to patients with type 1 diabetes
patients with CFRD have a similar incidence of
microvascular disease with a lower prevalence
of retinopathy and a higher prevalence of
microalbuminuria [33]. Screening for
microvascular complications is likely to
increase in importance with increasing
longevity of patients with CFRD.
TREATMENT OF HYPERGLYCAEMIA
Unlike other forms of diabetes where control of
glucose is primarily to prevent microvascular
and macrovascular complications, the main
goal in CFRD is prevention and improvement
of declining respiratory function and
nutritional status. Several small
non-randomised studies, retrospective reviews
and case series have suggested a benefit of
insulin in both reducing the decline of lung
function and weight loss. These studies use a
variety of insulins with various levels of
glycaemia and clinical triggers for patient
selection [34–37]. We have reported
retrospective, observational data from our
unit, which suggest that introducing insulin at
the stage of impaired glucose tolerance seems to
ameliorate loss of lung function and increase
weight [38]. One open-label randomised study
attempted to assess the impact on clinical
outcomes of preprandial insulin treatment
compared to repaglinide and placebo in
patients with CFRD but no fasting
hyperglycaemia. There was no change in
decline in lung function or infections in the
insulin group at 12 months, but there was a
significant improvement in BMI. It was felt that
the short duration of the study made it unlikely
that changes in lung function would have been
detected [39]. A systematic review performed by
the National Institute for Health Research
concluded that insulin appears beneficial in
CFRD and probably at the IGT stage [24].
Hypoglycaemia is an obvious potential risk
when using insulin in CF patients.
Table 2 Suggested criteria for diagnosis of CFRD (Adapted from ADA guidelines [16])
Patient status Suggested diagnostic glucose level (mmol/l) (all CBG results to be conﬁrmed
by laboratory measurement)
Healthy outpatients 75 G OGTT fasting C7 or 2 h C11.1
Random[11.1 on 2 measures with osmotic symptoms, declining weight or
lung function
Enteral tube feeding C11.1 during feed on 2 occasions
Acute illness or steroid use Fasting C7
Random C11.1 on 2 occasions over 48 h
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Hypoglycaemia can be observed in CF patients
even before they have treatment for
dysglycaemia, perhaps suggesting a mismatch
between the increased late insulin secretion and
rapid carbohydrate absorption [40]; 6.1% of
CBG measurements performed in hospitalised
patients with CF who were treated with insulin
were found to be in the hypoglycaemia range
(\4.0 mmol/l). Hypoglycaemia was also found
to be associated with a significantly higher rate
of readmission or death over the 3.5-year
follow-up period (P = 0.03) [41]. This is a
higher rate of hypoglycaemia than that
previously reported in the general population
of inpatients with diabetes [42]. Hypoglycaemia
in CF patients treated with insulin has also been
associated with high levels of loss of awareness
of hypoglycaemia, which may reflect loss of
glucagon response or high exposure to
hypoglycaemic range glucose [38]. It is
therefore important to balance the potential
benefit of insulin use in CF with the burden and
harm of hypoglycaemia.
Continuous subcutaneous insulin infusion
(CSII) by pump would seem in theory to offer
significant potential advantages of flexibility
and avoidance of hypoglycaemia, which could
be of particular benefit in CFRD. Despite this
CSII is not commonly used in patients with
CFRD, perhaps reflecting increased cost or a
feeling that CSII may be too much of a burden
to patients already requiring intensive medical
intervention [43].
There have been some small studies of
insulin secretagogues showing reductions in
glucose levels in CFRD; however none have
shown significant benefit to important
outcomes of lung function or weight [39, 44].
We do not presently recommended the use of
insulin secretagogues in CFRD.
It is our local practice to consider insulin
initiation where hyperglycaemia
(glucose[11.1 mmol/l) is detected either by
screening or clinical monitoring triggered by
clinical concern such as where the patients has
poor nutritional status, declining lung function
or recurrent lung infection. We favour the use
of the prandial insulin bolus initially in the
majority of cases for reasons of flexibility and as
postprandial hyperglycaemia is usually the
primary abnormality. We add basal insulin
when fasting glucose becomes abnormal or
bolus requirements become high.
There is insufficient evidence to be dogmatic
about what glycaemic target should be aimed
for in patients with CFRD. The ADA
recommend achieving the same target CBG
levels as those with type 1 diabetes
(preprandial 4.4–7.2 mmol/l and
postprandial\10 mmol/l) [16, 45]. This seems
a reasonable goal, and patients should be
encouraged to perform CBG testing regularly
including postprandially if possible. Table 3
suggests a guideline for management of
glucose abnormalities in CF with insulin.
IMPACT OF OTHER THERAPIES
Nutritional status is of great importance in CF
patients who have both increased resting energy
expenditure and increased loss of calories
through malabsorption and in whom cachexia
is known to worsen outcome [46]. Optimising
nutritional status is therefore an important
goal, which has been shown to improve the
ability to undertake normal daily activities [47].
Patients with CF are therefore recommended to
take a high calorie diet (usually 120–150% of
the daily recommended intake for age) [16]. To
maintain high calorific intake enteral tube
feeding (ETF) is commonly utilised and is
thought to improve outcome [48]. Schedules
for tube feeding vary and take into account the
patient’s schedule and other treatments,
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making evidence-based guidelines used in other
settings for control of glucose during ETF less
applicable [49]. Our experience suggests that
liaisoning between the diabetes team and
specialist dieticians is crucial when planning
ETF. In CF patients ETF is often performed at
home and overnight, and timing of feeds can
vary from 4–12 h. Variation in the timing and
tolerability of ETF can make choosing the
optimum insulin to maximise energy
conservation from the feed challenging.
Choice of insulin should be made by matching
the duration of insulin action to the agreed
enteral feeding regimen. Dosing and insulin
type can then be altered dependent on CBG
readings before, during, and after ETF starts.
Overnight CBG monitoring during ETF will
disturb sleep and is therefore particularly
burdensome to patients.
Use of steroids (usually prednisolone or
methylprednisolone) has been common in
patients with CF and can cause transient
hyperglycaemia or worsen glucose control in
existing CFRD. It has been reported that over
50% of CFRD patients who have been admitted
to hospital will have had at least one course of
steroid treatment [50]. There is little evidence to
guide management of hyperglycaemia related to
steroid use in the general population let alone in
CFRD. National guidelines suggest enhanced
CBG monitoring and the use of insulin to
correct hyperglycaemia [51]. We recommend
CBG monitoring of fasting and postprandial
glucose in all CF patients started on steroids.
SUMMARY
Glucose abnormalities related to CF pose
unique challenges to both diabetes and
respiratory teams. The close associations
between worsening dysglycaemia and poor
outcome suggest benefit from insulin
replacement therapy, but the time to start
treatment and desired CBG levels remain
Table 3 Suggested approach (based on or local practice) to insulin treatment in CFRD
Reason to commence Starting dose Optimal target glucose
Prandial bolus insulin 1–2 h postprandial
glucose[11.1 mmol/l
With clinical indicationa
0.5 units per 10 g CHO 1–2 h postprandial glucose
\10 mmol/l
Basal insulin If fasting[7.2 mmol/l or if
boluses needed greater
than 1.5 units per 10 g
CHO
Add 0.1 unit per kg either
long acting insulin (e.g.,
glargine) morning or
intermediate acting (e.g.,
insulatard) night if fasting




Enteral tube feeding insulin 6–8 h feed with
glucose[11.1 mmol/l
4–6 h feed with
glucose[11.1 mmol
Add insulatard 0.5 units per
10 g CHO
Add actrapid 0.5 units per
10 g CHO
During or end of feed
\10 mmol/l
Existing and required dose of insulin may double during acute illness and steroid therapy
a Osmotic symptoms, weight loss, recurrent lung infection, or decline in lung function
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controversial. Insulin therapy has significant
potential to cause harm—especially by inducing
hypoglycaemia. At present we recommend a
pragmatic multidisciplinary approach to
managing this complex area. We suggest
insulin use targeting postprandial glucose
excursions, initiated when risks of declining
lung function and nutritional status are high.
We use postprandial CBG measurements to
guide insulin dosing along with pre-prandial
and fasting CBG measurement to guard against
hypoglycaemia. Further data would be
welcomed on the optimum timing of insulin
initiation and on the glycaemic targets that
would best prevent decline in lung function.
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